I just received an email from a friend to suggest it is available. I’m to start 6 months of BR treatment on Monday 12th January, and would be so relieved if I can try a non-chemotherapy drug instead.
Dear Healthcare Professional
I am pleased to inform you that Janssen UK has been granted European Medicines Agency (EMA) marketing authorisation for IMBRUVICA® (ibrutinib) in the United Kingdom.
Prescribing information can be found at the end of this email.
IMBRUVICA® is indicated for the treatment of adult patients with:
• Relapsed or refractory mantle cell lymphoma (MCL). 1
• Chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. 1